PharmaLogic Offcially Opens New Radiopharmaceutical Facility in Los Angeles

• PharmaLogic has opened a newly renovated radiopharmaceutical production and research facility in Los Angeles, California.

• The facility aims to expand the company’s manufacturing and research capabilities, focusing on developing novel radiopharmaceuticals.

PharmaLogic Holdings Corp. , a contract development and manufacturing organisation (CDMO) specialising in radiopharmaceutical solutions, has officially opened its Los Angeles facility following extensive renovations. Acquired in 2022, this state-of-the-art centre is equipped with advanced technology to support the production and research of innovative radiopharmaceuticals.

The Los Angeles site is part of PharmaLogic’s strategic investment to support collaboration with healthcare providers and researchers. The facility will work on expanding access to radiopharmaceutical diagnostics for local patients, according to CEO Steve Chilinski. “Being in Los Angeles enables us to collaborate with leading healthcare providers and researchers promoting the development of novel radiopharmaceuticals and expanding patient access,” he commented.

PharmaLogic’s Los Angeles expansion will boost both production and R&D efforts in the field of molecular imaging and theranostics. Scott Holbrook, Chief Strategy Officer and General Manager, noted the company’s commitment to advancing healthcare diagnostics: “Our investment in production and research capabilities is a testament to our commitment to improving patient outcomes through advancements in molecular imaging and theranostics.”